CorMedix Inc. (CRMD) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped CRMD stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: CorMedix Inc. presents an exceptional growth opportunity, driven by extraordinary projected revenue growth, strong product appeal (e.g., Neutrolin), and strategic expansion efforts. Regulatory risks and trial delays are noted, but the company's fundamentals, coupled with positive analyst sentiment and a strong growth-oriented pipeline, bolster a favorable long-term investment outlook. The saved 1-year distribution is P10 $6.2, P50 $14.2, and P90 $18.6.
Last analyzed · Model: gpt-4o
CorMedix Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $6.2 | Pessimistic plausible scenario |
| P50 | $14.2 | Median scenario |
| P90 | $18.6 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
CorMedix Inc. has fundamentally strong growth indicators, including a massive revenue growth estimation of 24260%. Analyst consensus of a strong buy and a median price target nearly double the current price strongly position the 1-year outlook as bullish. Positive catalysts like FDA approvals and expansions support this view.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this CRMD analysis generated?
April 21, 2026.
Is this a guaranteed CRMD prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full CRMD stock analysis · CRMD sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.